1. Ability to provide written informed consent. <br/ >2. Participants of either gender age between �18 to �55 years. (Phase 1) <br/ >3. Participants of either gender age between �12 to �65 years. (Phase2) <br/ >4. Good general health as determined by the discretion of investigator (vital signs <br/ >(Pulse rate �60 to�100 bpm, blood pressure systolic �90 mm Hg and <140 mm <br/ >Hg, diastolic � 60 mm Hg and <90 mm Hg, oral temperature <100.4ºF), <br/ >medical history, and physical examination). <br/ >5. Expressed interest and availability to fulfil the study requirements. <br/ >6. For a female participant of child-bearing potential, avoid becoming pregnant <br/ >(use of an effective method of contraception or abstinence) from the time of <br/ >study enrolment until at least 4 weeks after the last vaccination and agrees not <br/ >to participate in another clinical trial at any time during the study period. <br/ >7. Sexually active men who are considered sexually fertile must agree to use a <br/ >barrier method of contraception and agree to continue the use for at least 3 <br/ >months following the last vaccination, or have a partner who is permanently <br/ >sterile or is medically unable to become pregnant. <br/ >8. Male subjects agree to refrain from sperm donation from the time of first <br/ >vaccination until 3 months after last vaccination. <br/ >9. Participants must refrain from blood or plasma donation from the time of first <br/ >vaccination until 3 months after last vaccination. <br/ >10. Agrees to remain in the study area for the entire duration of the study. <br/ >11. Willing to allow storage and future use of biological samples for future <br/ >research. <br/ >

1. Ability to provide written informed consent. <br/ >2. Participants of either gender age between �18 to �55 years. (Phase 1) <br/ >3. Participants of either gender age between �12 to �65 years. (Phase2) <br/ >4. Good general health as determined by the discretion of investigator (vital signs <br/ >(Pulse rate �60 to�100 bpm, blood pressure systolic �90 mm Hg and <140 mm <br/ >Hg, diastolic � 60 mm Hg and <90 mm Hg, oral temperature <100.4ºF), <br/ >medical history, and physical examination). <br/ >5. Expressed interest and availability to fulfil the study requirements. <br/ >6. For a female participant of child-bearing potential, avoid becoming pregnant <br/ >(use of an effective method of contraception or abstinence) from the time of <br/ >study enrolment until at least 4 weeks after the last vaccination and agrees not <br/ >to participate in another clinical trial at any time during the study period. <br/ >7. Sexually active men who are considered sexually fertile must agree to use a <br/ >barrier method of contraception and agree to continue the use for at least 3 <br/ >months following the last vaccination, or have a partner who is permanently <br/ >sterile or is medically unable to become pregnant. <br/ >8. Male subjects agree to refrain from sperm donation from the time of first <br/ >vaccination until 3 months after last vaccination. <br/ >9. Participants must refrain from blood or plasma donation from the time of first <br/ >vaccination until 3 months after last vaccination. <br/ >10. Agrees to remain in the study area for the entire duration of the study. <br/ >11. Willing to allow storage and future use of biological samples for future <br/ >research. <br/ >

1. Ability to provide written informed consent. <br/ >2. Participants of either gender age between �18 to �55 years. (Phase 1) <br/ >3. Participants of either gender age between �12 to �65 years. (Phase2) <br/ >4. Good general health as determined by the discretion of investigator (vital signs <br/ >(Pulse rate �60 to�100 bpm, blood pressure systolic �90 mm Hg and <140 mm <br/ >Hg, diastolic � 60 mm Hg and <90 mm Hg, oral temperature <100.4ºF), <br/ >medical history, and physical examination). <br/ >5. Expressed interest and availability to fulfil the study requirements. <br/ >6. For a female participant of child-bearing potential, avoid becoming pregnant <br/ >(use of an effective method of contraception or abstinence) from the time of <br/ >study enrolment until at least 4 weeks after the last vaccination and agrees not <br/ >to participate in another clinical trial at any time during the study period. <br/ >7. Sexually active men who are considered sexually fertile must agree to use a <br/ >barrier method of contraception and agree to continue the use for at least 3 <br/ >months following the last vaccination, or have a partner who is permanently <br/ >sterile or is medically unable to become pregnant. <br/ >8. Male subjects agree to refrain from sperm donation from the time of first <br/ >vaccination until 3 months after last vaccination. <br/ >9. Participants must refrain from blood or plasma donation from the time of first <br/ >vaccination until 3 months after last vaccination. <br/ >10. Agrees to remain in the study area for the entire duration of the study. <br/ >11. Willing to allow storage and future use of biological samples for future <br/ >research. <br/ >

1. Ability to provide written informed consent. <br/ >2. Participants of either gender age between �18 to �55 years. (Phase 1) <br/ >3. Participants of either gender age between �12 to �65 years. (Phase2) <br/ >4. Good general health as determined by the discretion of investigator (vital signs <br/ >(Pulse rate �60 to�100 bpm, blood pressure systolic �90 mm Hg and <140 mm <br/ >Hg, diastolic � 60 mm Hg and <90 mm Hg, oral temperature <100.4ºF), <br/ >medical history, and physical examination). <br/ >5. Expressed interest and availability to fulfil the study requirements. <br/ >6. For a female participant of child-bearing potential, avoid becoming pregnant <br/ >(use of an effective method of contraception or abstinence) from the time of <br/ >study enrolment until at least 4 weeks after the last vaccination and agrees not <br/ >to participate in another clinical trial at any time during the study period. <br/ >7. Sexually active men who are considered sexually fertile must agree to use a <br/ >barrier method of contraception and agree to continue the use for at least 3 <br/ >months following the last vaccination, or have a partner who is permanently <br/ >sterile or is medically unable to become pregnant. <br/ >8. Male subjects agree to refrain from sperm donation from the time of first <br/ >vaccination until 3 months after last vaccination. <br/ >9. Participants must refrain from blood or plasma donation from the time of first <br/ >vaccination until 3 months after last vaccination. <br/ >10. Agrees to remain in the study area for the entire duration of the study. <br/ >11. Willing to allow storage and future use of biological samples for future <br/ >research. <br/ >